Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273102 | 1.00 | OPRL1 (0.38) | OPRL1HPGDEPHX2KMT2AMEN1 | |
| SCHEMBL2273096 | 1.00 | OPRL1 (0.38) | OPRL1HPGDEPHX2KMT2AMEN1 | |
| SCHEMBL2272932 | 0.89 | IDO1 (0.39) | OPRL1EPHX2LMNAALDH1A1 | |
| SCHEMBL2272928 | 0.89 | IDO1 (0.39) | OPRL1EPHX2LMNAALDH1A1 | |
| SCHEMBL2272930 | 0.89 | IDO1 (0.39) | OPRL1EPHX2LMNAALDH1A1 | |
| SCHEMBL2275642 | 0.78 | OPRL1 (0.39) | OPRL1HPGDEPHX2KMT2AMEN1 | |
| SCHEMBL2275637 | 0.78 | OPRL1 (0.39) | OPRL1HPGDEPHX2KMT2AMEN1 | |
| SCHEMBL2272589 | 0.69 | OPRL1 (0.39) | OPRL1EPHX2KMT2AMEN1PROKR1 | |
| SCHEMBL2274559 | 0.69 | HPGDS (0.39) | OPRL1EPHX2KMT2AMEN1LMNA | |
| SCHEMBL2274562 | 0.69 | HPGDS (0.39) | OPRL1EPHX2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | OPRL1 520/4885HPGD 170/4885EPHX2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.